-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Patients with Glone-negative infections with carbon penicillin are in urgent need of new antibiotic drugs.
researchers recently assessed the efficacy and safety of cephalosporine against severe carbon penicillin-like gloran-negative infections in adults.
The study was conducted in 95 hospitals in 16 countries in North America, South America, Europe and Asia, involving patients admitted to hospitals aged 18 years or older with pneumonia, blood flow infections or sepsis, or complications of urinary tract infections (UTI), and patients with evidence of Glollabyl-negative pathogens resistant to carbon penicillin.
receive 3h intravenous cephalosporine (2 g) or other treatment every 8 hours (pre-designated by the researchers before random grouping, consisting of up to three drugs) for 7-14 days.
For patients with pneumonia, blood flow infections, or sepsis, cephalosporins can be treated in a combined way with an auxiliary antibiotic (excluding polysporine, cephalosporins, and carbon penicillin).
end point for patients with hospital-approved pneumonia, blood flow infections or sepsis is clinical cure rate (ITT).
for complex UTI patients, the main endpoint is microbial eradication.
150 patients participated in the study, 101 patients received cephalosporine treatment, 49 patients received other treatment, 85 cases (85%) of cephalosporine group received single-drug treatment, and 30 patients (61%) of other treatment groups received combined treatment.
most common carbon penicillin-resistant pathogens were Bowman's Bacillus (46%), Krepium pneumonia (33%) and copper-green protons (19%).
For patients with hospital-approved pneumonia, 20 (50%) of the 40 cases in the cephalosporine group and 10 (53%) of the 19 patients in the other treatment groups received clinical cures;
for complex UTIs patients, microbial eradication was achieved in 9 out of 17 patients in the cephalosporine group (53%) and 1 in 5 patients (20%) in the other treatment groups.
treatment-emergency adverse events occurred in 91% of patients in the cephalosporine group and 96% in other treatment groups.
34 percent of patients in cephalosporine and 18 percent of patients in other treatment groups died at the end of the study, one of which (other treatment groups) was thought to be related to the drug.
study concluded that cephalosporine has better clinical and microbiological efficacy in the group of infected patients caused by carbon penicillin-resistant Terrain-negative bacteria, although the number of deaths in the cephalosporine group is higher, but mainly concentrated in the subgroups of patients infected with Bacillus.
, the results support cephalosporine as a treatment drug for a limited choice of carbon penicillin-resistant infections.
.